Tag: Ai in medicine

Forecasts predict that between 2025 and 2050, bacterial antimicrobial resistance (AMR) will be directly responsible for 39 million deaths globally [1.6.3]. Amid this crisis, the critical question remains: are new antibiotics being discovered quickly enough to counter this threat?

According to a recent industry analysis, the market for in silico technologies was valued at approximately $8.3 billion in 2022, demonstrating its significant impact on pharmaceutical research. This article explores what is the meaning of in silico drug discovery, explaining how it uses computational techniques to accelerate and refine the development of new medicines.

The global AI in drug discovery market was valued at $1.5 billion in 2023 and is projected to soar to $20.30 billion by 2030 [1.9.5]. This explosion in technology is accelerating the hunt for the answer to the question: **what is the next big drug?**

While the term GPT is now widely associated with artificial intelligence (AI), in the context of pharmacy, it has at least three distinct meanings spanning clinical diagnostics, quality control, and cutting-edge technology. Understanding **what does GPT stand for in pharmacy** requires differentiating between these contexts to avoid confusion and properly apply the term.

GPT is not a drug, but rather an acronym that stands for different concepts in medicine and artificial intelligence. The misconception of a "GPT drug" arises from the overlap of generative pre-trained transformers (GPTs) and their increasing application within pharmaceutical research, leading to AI-powered tools that assist with drug development and medication safety.